< Back to previous page
Researcher
Sandra Tuyaerts
- Keywords (Vrije Universiteit Brussel):Medicine
- Disciplines (Vrije Universiteit Brussel):Cancer biology, Cancer therapy, Immunology not elsewhere classified
- Disciplines (KU Leuven):Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
- See also: Sandra Tuyaerts (Vrije Universiteit Brussel)
Affiliations
- Laboratory for Medical and Molecular Oncology (Research group)
Member
From1 Nov 2022 → Today - Medical Oncology (Department)
Member
From1 May 2020 → Today - Clinical sciences (Department)
Member
From1 Feb 2021 → Today - Clinical sciences (Department)
Member
From1 Feb 2021 → 20 Oct 2022 - Clinical sciences (Department)
Member
From1 Jun 2020 → Today - Clinical sciences (Department)
Member
From1 Jun 2020 → 20 Oct 2022 - Gynaecological Oncology (Division)
Member
From16 Nov 2009 → 31 Dec 2022 - Physiology (Department)
Member
From1 Oct 1999 → 30 Apr 2008 - Physiology (Department)
Member
From1 Oct 1999 → 30 Apr 2008
Publications
1 - 10 of 34
- Trial watch: Dendritic cell (DC)-based immunotherapy for cancer(2022)
Authors: Jenny Sprooten, Stefan Naulaerts, Benoit Beuselinck, An Coosemans, Lisa Kinget, Sandra Tuyaerts, Steven De Vleeschouwer, Abhishek Garg
- Intratumoral administration of CD1c (BDCA-1)(+) and CD141 (BDCA-3)(+) myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial(2022)
Authors: Sandra Tuyaerts
- Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells(2021)
Authors: Sandra Tuyaerts
- A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma(2021)
Authors: Sandra Tuyaerts
Pages: S832 - S833 - Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): A multi-cohort adaptive phase I clinical trial(2021)
Authors: Sandra Tuyaerts
Pages: S516 - S517 - Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?(2021)
Authors: Regina Esi Mensimah Baiden-Amissah, Daniela Annibali, Sandra Tuyaerts, Frédéric Amant
- Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?(2021)
Authors: Wout De Wispelaere, Daniela Annibali, Sandra Tuyaerts, Diether Lambrechts, Frédéric Amant
- Intratumoral Combinatorial Administration of CD1c (BDCA-1)(+) Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial(2020)
Authors: Sandra Tuyaerts
- Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer(2020)
Authors: Daniela Annibali, Sandra Tuyaerts, Frédéric Amant
- The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer(2020)
Authors: Daniela Annibali, Sandra Tuyaerts, Frédéric Amant